Hematological Malignancies: Current Perspectives on Diagnosis, Prognosis, and Treatment.

Article

This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today.

This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today: chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute myeloid leukemia. This supplement is supported by an educational grant from Cephalon Oncology, and is jointly sponsored by Postgraduate Institute for Medicine and Vital Issues in Medicine. CME/PE/CE credit is available. 
Continue To Supplement...

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024
Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management

February 5th 2024
Podcast

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.

Nanatinostat Combo Yields Responses in R/R EBV+ Peripheral T-Cell Lymphoma

April 18th 2024
Article

Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

November 3rd 2022
Podcast

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL

STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL

April 15th 2024
Article

Additional data and results from the phase 3 STARGLO trial of glofitamab for patients with relapsed/refractory diffuse large B-cell lymphoma will be presented at an upcoming medical meeting.

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

April 14th 2024
Article

HR001 was found to have an efficacious response for patients with relapsed/refractory non-Hodgkin lymphoma.